Neuroreceptor Imaging of Stress and Mood Disorders

CNS Spectrums

Volumn 9, Issue 4, 2004, Pages 292-301

  Kennedy, Susan E ^a   Zubieta, Jon Kar ^b,c,d,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Neuroscience Program   (United States)

^c Mental Health Service   (United States)

^d University of Michigan Depression Center   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PIPERIDYL BENZILATE; 1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 3 METHYLSPIPERONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALTANSERIN; AMPHETAMINE; BENZAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; CARFENTANIL; CYCLOFOXY; DIHYDROTETRABENAZINE; DIPRENORPHINE; DOPAMINE TRANSPORTER; FLUMAZENIL; IODOBENZAMIDE; IODOBENZOFURAN IN I 123; IOMAZENIL; KETANSERIN; LIGAND; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTRANSMITTER RECEPTOR; NORCITALOPRAM; OPIATE RECEPTOR; R 91150; RACLOPRIDE; SEROTONIN TRANSPORTER; SETOPERONE; SPIPERONE DERIVATIVE; TROPANE DERIVATIVE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIPOLAR DISORDER; BRAIN FUNCTION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOOD DISORDER; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PAIN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS;

EID: 2342441927     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900009238     Document Type: Review

References (80)

1. Fox PT, Raichle ME. Stimulus rate dependence of regional cerebral blood flow in human striate cortex, demonstrated by positron emission tomography. J Neurophysiol. 1984;51:1109-1120.
2. Kadekaro M, Crane AM, Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci U S A. 1985;82:6010-6013.
3. George MS, Ketter TA, Parekh PI, Horwitz B, Herscovitch P, Post RM. Brain activity during transient sadness and happiness in healthy women. Am J Psychiatry. 1995;152:341-351.
4. Adolphs R, Damasio H, Tranel D, Damasio AR. Cortical systems for the recognition of emotion in facial expressions. J Neurosci. 1996;16:7678-7687.
5. Breiter HC, Etcoff NL, Whalen PJ, et al. Response and habituation of the human amygdala during visual processing of facial expression. Neuron. 1996;17:875-887.
6. Morris JS, Friston KJ, Büchel C, et al. A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain. 1998;121:47-57.
7. Taylor SF, Liberzon I, Fig LM, Decker LR, Minoshima S, Koeppe RA. The effect of emotional content on visual recognition memory: a PET activation study. Neuroimage. 1998;8:188-197.
8. Davidson R, Irwin W. The functional neuroatomy of emotion and affective style. Trends Cognit Sci. 1999;3:11-21.
9. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675-682.
10. Calder A, Lawrence A, Young A. Neuropsychology of fear and loathing. Nature Rev Neurosci. 2001;2:352-363.
11. Phan KL, Taylor SF, Welsh RC, et al. Activation of the medial prefrontal cortex and extended amygdala by individual ratings of emotional arousal: a fMRI study. Biol Psychiatry. 2003;53:211-215.
12. Bench CJ, Frackowiak RS, Dolan RJ. Changes in regional cerebral blood flow on recovery from depression. Psychol Med. 1995;25:247-261.
13. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A. 1996;93:3908-3913.
14. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824-827.
15. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci. 1997;9:471-481.
16. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375-1387.
17. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174-180.
18. Cidis Meltzer C, Drevets WC, Price JC, et al. Gender-specific aging effects on the serotonin 1A receptor. Brain Res. 2001;895:9-17.
19. Biver F, Goldman S, Luxen A, et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med. 1994;21:937-946.
20. Sadzot B, Lemaire C, Maquet P, et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab. 1995;15:787-797.
21. Shiue CY, Shiue GG, Mozley PD, et al. P-[18F]-MPPF: a potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse. 1997;25:147-154.
22. Costes N, Merlet I, Zimmer L, et al. Modeling [18F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab. 2002;22:753-765.
23. D'Haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L. SPECT imaging of serotonin2 receptors in depression. Psychiatry Res. 1992;45:227-237.
24. Versijpt J, Van Laere KJ, Dumont F, et al. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol Aging. 2003;24:553-561.
25. Zanardi R, Artigas F, Moresco R, et al. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol. 2001;21:53-58.
26. Yatham LN, Liddle PF, Shiah IS, et al. Brain serotonin 2 receptors in major depression. A positron emission tomography study. Arch Gen Psychiatry. 2000;57:850-858.
27. Yatham LN, Liddle PF, Dennie J, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry. 1999;56:705-711.
28. Attar-Lévy D, Martinot JL, Blin J, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry. 1999;45:180-186.
29. Meyer JH, Kapur S, Houle S, et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry. 1999;156:1029-1034.
30. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001;158:78-85.
31. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry. 1995;52:471-477.
32. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258-261.
33. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse. 1994;16:255-262.
34. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology. 2001;25:476-488.
35. Farde L, Nordstrom AL, Halldin C, Wiesel FA, Sedvall G. PET studies of dopamine receptors in relation to antipsychotic drug treatment. Clin Neuropharmacol. 1992;15(suppl 1 pt A):468A-469A.
36. Hirvonen J, Nagren K, Kajander J, Hietala J. Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: a test-retest analysis. J Cereb Blood Flow Metab. 2001;21:1133-1145.
37. Larisch R, Klimke A, Vosberg H, et al. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5:251-260.
38. Anand A, Verhoeff P, Seneca N, et al. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000;157:1108-1114.
39. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50:313-322.
40. Laruelle M, van Dyck C, Abi-Dargham A, et al. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med. 1994;35:743-754.
41. Ichimiya T, Suhara T, Sudo Y, et al. Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry. 2002;51:715-722.
42. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression; a [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843-1849.
43. Bergstrom KA, Halldin C, Hall H, Lundkvist C, Ginovart N, Swahn CG, Farde L. In vitro and in vivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med. 1997;24:596-601.
44. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44:1090-1098.
45. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F] CFT PET. Synapse. 2003;48:109-115.
46. Fowler JS, Volkow ND, Wang GJ, Gatley SJ, Logan J. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol. 2001;28:561-572.
47. Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse. 1994;16:93-103.
48. Davis MR, Votaw JR, Bremner JD, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855-861.
49. Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, Dolle F, Peschanski M, Hantraye P, Cesaro P, Samson Y, Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol. 2002;59:580-586.
50. Martinot M, Bragulat V, Artiges E, et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 2001;158:314-316.
51. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry. 2002;159:768-774.
52. Yatham LN, Liddle PF, Lam RW, et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry. 2002;159:1718-1723.
53. Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A. 1997;94:5308-5313.
54. Frey KA, Koeppe EA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873-884.
55. Zubieta JK, Smith YR, Bueller JA, et al. Regional mu-opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311-315.
56. Zubieta JK, Smith YR, Bueller JA, et al. mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci. 2002;22:5100-5107.
57. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243.
58. Liberzon I, Zubieta JK, Fig LM, et al. mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A. 2002;99:7084-7089.
59. Jones AK, Cunningham VJ, Ha-Kawa S, et al. Changes in central opioid receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis. Br J Rheumatol. 1994;33:909-916.
60. Kling MA, Carson RE, Borg L, et al. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070-1076.
61. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet. 1988;2:863-866.
62. Chugani DC, Muzik O, Juhasz C, Janisse JJ, Ager J, Chugani HT. Postnatal maturation of human GABAA receptors measured with positron emission tomography. Ann Neurol. 2001;49:618-626.
63. Beer HF, Blauenstein PA, Hasler PH, et al. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med. 1990;31:1007-1014.
64. Innis RB, al-Tikriti MS, Zoghbi SS, Baldwin RM, Sybirska EH, Laruelle MA, Malison RT, Seibyl JP, Zimmermann RC, Johnson EW, et al. SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves. J Nucl Med. 1991;32:1754-1761.
65. Kumlien E, Hartvig P, Valind S, Oye I, Tedroff J, Langstrom B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia. 1999;40:30-37.
66. Zubieta JK, Koeppe RA, Mulholland GK, Kuhl DE, Frey KA. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. J Cereb Blood Flow Metab. 1998;18:619-631.
67. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry. 1998;44:534-549.
68. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12(suppl 1):2-19.
69. Middlemiss DN, Price GW, Watson JM. Serotonergic targets in depression. Curr Opin Pharmacol. 2002;2:18-22.
70. Azmitia E, Whitaker-Azmitia P. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry. 1991;52(suppl 12):4-16.
71. Cowen PJ, Power AC, Ware CJ, Anderson IM. 5-HT1A receptor sensitivity in major depression: a neuroendocrine study with buspirone. Br J Psychiatry. 1994;164:372-379.
72. Meltzer HY, Maes M. Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biol Psychiatry. 1995;38:450-457.
73. Lopez JF, Chalmers DT, Little KY, et al. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry. 1998;43:547-573.
74. Bowen DM, Najlerahim A, Procter AW, et al. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci U S A. 1989;86:9504-9508.
75. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry. 1960;23:56-62.
76. Klimek V, Schenck JE, Han H, et al. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002;52:740-748.
77. Tremblay LK, Naranjo CA, Cardenas L, Herman N, Busto NE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002;59:409-416.
78. Klimke A, Larisch R, Janz A, et al. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 1999;90:91-101.
79. Ebert D, Feistel H, Loew T, et al. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl). 1996;126:91-94.
80. Zubieta JK, Huguelet P, Ohl LE, et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry. 2000;157:1619-1628.